August 15, 2008

Nomir Medical to Present Positive Onychomycosis Data for Its Noveon(R) Dual Wavelength Device

Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced today that the Company will present an abstract detailing positive in vitro and in vivo human data from its study of onychomycosis (toe nail fungus) using Noveon(R), a novel dual wavelength optical energy device. Noveon is designed to effect near-infrared photo-inactivation of fungi and bacteria at energies and temperatures that are safe to normal and healthy tissue.

The detailed data will be presented in a digital session at the New Cardiovascular Horizons "Wound Management of the Diabetic Foot and Wound Healing" conference in New Orleans, September 10-13, 2008.

In May 2008, Nomir initiated a pivotal product registration trial for Noveon for the onychomycosis indication.

About Nomir

Nomir Medical Technologies, Inc. is a medical device company with a product pipeline of optical energy therapeutics being developed for multiple clinical applications. Nomir's light-based systems target the elimination of bacterial and fungal infections, while also promoting healthy tissue recovery. This potential therapy-altering technology may enhance the effectiveness of, or even reduce the need for antibiotics and antifungal agents, and may be associated with fewer treatment side-effects. Nomir has a broad patent portfolio with pending systems, methods and unique photobiological mechanism claims for near infrared photodamage to bacterial and fungal pathogens.

Forward-looking statements

Certain statements contained in this press release containing words like believe, intend, may, expect, project and other similar expressions are forward-looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technologies; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the Company's announcements.